Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated participants ...
The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...
The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
Share on Pinterest Researchers are hopeful that a new drug can help treat the symptoms of a rare type of ALS. herraez/Getty Images The Food and Drug Administration (FDA) has approved the drug toferson ...
Apic Bio Receives FDA Fast Track Designation for APB-102 for the Treatment of Patients with SOD1 ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that the U.S. Food and ...
When Biogen’s experimental treatment for amyotrophic lateral sclerosis (ALS) missed the main goal of a pivotal study last year, the drugmaker said further analysis could yield better results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results